pentobarbital will reduce the extent or outcome of fosamprenavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.

pentobarbital will decrease the level or influence of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital raises toxicity of ifosfamide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. CYP3A4 inducers may perhaps raise the metabolism of ifosfamide to its active alkylating metabolites.

pentobarbital will raise the stage or outcome of ivosidenib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration of ivosidenib with robust CYP3A4 inducers decreased ivosidenib plasma concentrations.

pentobarbital will decrease the level or outcome of estradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.

pentobarbital will lower the level or result of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.

Either will increase toxicity of one other by pharmacodynamic synergism. Steer clear of or Use Alternate Drug. Profound sedation, respiratory depression, coma, and Loss of life may possibly consequence if coadministered. Reserve concomitant prescribing of such drugs in patients for whom other remedy possibilities are inadequate. Limit dosages and durations for the minimal required. Monitor intently for indications of respiratory despair and sedation.

pentobarbital will lower the level or influence of parecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Observe.

In case the dose from the concomitant CYP3A4 inducer can't be reduced or discontinued, implant elimination could be vital along with the affected individual must then be addressed with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inducer here is discontinued in the affected person who has become stabilized on buprenorphine, observe the client for overmedication.

pentobarbital will reduce the level or influence of aprepitant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.

If a CYP3A4 inducer is discontinued in the individual who has long been stabilized on buprenorphine, watch the patient for overmedication.Severe - Use Alternate (one)buprenorphine subdermal implant and pentobarbital the two improve sedation. Steer clear of or Use Alternate Drug. Restrict use to patients for whom different therapy alternatives are insufficient

With therapeutic doses of TCAs, barbiturates raise metabolism and decrease blood concentrations of TCAs.

Soon after halting a CYP3A4 inducer, given that the effects on the inducer decrease, the fentanyl plasma focus will improve which could raise or lengthen the two the therapeutic and adverse effects.

pentobarbital will decrease the extent or impact of paclitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Not known.